Abu Dhabi to host AstraZeneca Covid-19 antibody therapy study

Abu Dhabi to host a study Antibody therapy Created by AstraZeneca in the next 15 months.

AstraZeneca to collaborate with Sheikh Khalifa Medical City Hospital in Abu Dhabi on a real-world evidence study Avehilddesigned to help prevent infections in patients with weakened immune systems Coronavirus disease.

This multinational observational study was designed to provide key real-world data on the safety and efficacy of Evusheld.

It will support high-risk populations in the UAE and the wider Middle East and Africa region by building a body of evidence on how Evusheld can prevent Covid-19.

As many as 1,000 people in Abu Dhabi are expected to take part in the trial, which will run until the end of 2023.

“The risk of Covid-19 infection is far from over, especially for the immunocompromised and vulnerable,” said Dr. Nawal Al Kaabi, Chief Medical Officer of the Medical City, who led the study.

“Real-world evidence is essential to help us better understand how the virus evolves and build additional tools to protect at-risk populations.

“Beyond the pandemic, this innovative research will complement regional efforts to improve the quality of healthcare, advance the digitization of medical data, and meet the growing demand for locally derived clinical data that captures our unique demographics.”

It is estimated that about 2% of the world’s population has a compromised immune system that responds insufficiently or not at all to vaccination.

“As Covid-19 continues to cast a shadow on the world, it is important to continue to protect the health and safety of all members of the community, especially the most vulnerable who are more vulnerable to complications from Covid-19,” said Eva Turgonyi, AstraZeneca in the Gulf Cooperation Committee and Medical Director of Pakistan.

“Unfortunately, there is a group of patients where vaccination does not provide adequate protection.

“By collecting real-world data from the United Arab Emirates, we can better understand how AstraZeneca’s long-acting antibody combination, Evusheld, protects immunocompromised patients and enables them to return to their daily lives.”

produce antibodies

Evusheld is a “pre-exposure” treatment that can be used in adults and children 12 years of age and older who are not infected with the coronavirus.

This drug produces antibodies in patients who are immunocompromised due to a medical or immune condition.

It also targets people for whom vaccination is not recommended. People receiving this drug should not be currently infected or have been recently known to have been exposed to someone who has Covid.

Ministry of Health and Prevention December Approval for use of the drug in an emergencythe first shipment arrived in Abu Dhabi.

In a clinical trial, the drug was found to reduce the risk of developing symptomatic Covid by 77%, and protection lasted for at least six months after one dose.

March, AstraZeneca says its Evusheld treatment Retained neutralizing activity against the “emerging and highly propagated” Omicron BA.2 sub-variant.

Dr Jamal Mohammed Al Kaabi said: “We are delighted to see the results of our work together with our partners around the world to position Abu Dhabi as a leading healthcare destination and an incubator for innovation in life sciences,” Deputy Minister of Health and .

“Thanks to its advanced infrastructure, the emirate is able to attract global partnerships with renowned leaders in the health and pharmaceutical sectors who have chosen Abu Dhabi as a prime destination for innovative research projects.”

Updated: August 29, 2022 at 2:23 pm